Product Reports Resources Pricing Login Book a demo

Codexis

Biotech & Life Sciences · Redwood City, United States · Founded 2002 · IPO 2010

Biosciences company applying synthetic chemistry technologies to create improved versions of small molecule therapeutics

Valuation $158M
Revenue $74M

Talent graph

Codexis's talent

Book a demo to see the people
Employees mapped 241 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 8 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

5 investors on Codexis's cap table

Sourced from Dealroom's funding and investor records.

Series B+ 5 investors entered at this stage
Maxygen
Chevron Technology Ventures
Bio*One Capital
EDBI
CMEA Capital

Global footprint

Where Codexis has talent and traffic

Workforce by country
7 countries with
team presence
🇺🇸 United States94.5%
🇸🇬 Singapore1.8%
🇭🇺 Hungary1.2%
🇫🇷 France0.6%
🇨🇭 Switzerland0.6%
Top 5 of 7 shown
Web traffic by country
6.2K monthly visits
across markets
🇺🇸 United States61.3%
🇮🇳 India22.6%
🇯🇵 Japan14.5%
🇬🇧 United Kingdom1.6%
Top 4 markets shown

Patent intelligence

$502M patent portfolio · 222 active families

Estimated portfolio value
$502M
317.2% of market cap · 14.1× larger than top peer Synthorx ($36M)
222 active patent families
Where Codexis innovates BiochemistryBiological organismBiotechnologyCell biologyEnzyme

Where Codexis concentrates vs peers

Each axis is a top-10 topic across Codexis and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Codexis's 3 investments and acquisitions.

Every disclosed deal where Codexis appeared as a backer or acquirer, 2021–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Codexis's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Codexis's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Codexis

        An AI-synthesized read of the highest-engagement posts about Codexis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Codexis on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.